Search

• ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy

  Media

  ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/

  First published: 06 May 2015

• GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths

  Media

  GSK and Save the Children announce the launch of their third annual $1 million Healthcare Innovation Award.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-2015-call-for-developing-country-healthcare-innovations-to-reduce-child-deaths/

  First published: 15 July 2015

• GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension

  Media

  GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension/

  First published: 23 October 2015

• GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

  Media

  GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-patients-with-asthma/

  First published: 27 October 2015

• GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension

  Media

  GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris®

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-to-expand-indication-for-volibris-in-treatment-of-pulmonary-arterial-hypertension/

  First published: 24 November 2015

• GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD

  Media

  GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-studies-comparing-anoro-ellipta-with-seretide-diskus-and-advair-diskus-in-patients-with-copd/

  First published: 14 March 2014

• ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

  Media

  ViiV announced they have entered into an agreement with Janssen for the development and commercialisation of Tivicay® Edurant®.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-collaboration-with-janssen-to-investigate-single-tablet-regimen-for-maintenance-treatment-of-hiv-1/

  First published: 12 June 2014

• GSK and Amicus Therapeutics announce revised Fabry agreement

  Media

  GSK & Amicus announced that Amicus has obtained global rights to develop chaperone migalastat HCl as monotherapy for Fabry disease.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-announce-revised-fabry-agreement/

  First published: 20 November 2013

• ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US

  Media

  GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA.

  https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-approved-as-first-once-daily-dual-bronchodilator-for-the-treatment-of-copd-in-the-us/

  First published: 18 December 2013

• GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry

  Media

  GSK & University of Nottingham formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-university-of-nottingham-collaborate-to-create-centre-of-excellence-for-sustainable-chemistry/

  First published: 26 April 2012